12TH MICROBIOME R&D & BUSINESSCOLLABORATION FORUM: USA
9TH PROBIOTICS & PREBIOTICS CONGRESS: USA
6TH SKIN MICROBIOME & COSMECEUTICALSCONGRESS: USA
SAN DIEGO, USA
October 17-18 2024

#MicrobiomeForumwww.global-engage.com

WARM WELCOME

Global Engage is pleased to announce the 12th Microbiome, Probiotics & Prebiotics R&D andBusiness Collaboration Forum, which is confirmed to be held on October 17-18 in San Diego at
the La Jolla Marriott and co-located with the 6th Skin Microbiome & Cosmeceuticals Congress.
This world-renowned event which regularly attracts over 250 industry, academic, and investment leaders lastyear, enables the discussion of the most scientific cutting-edge microbiome, probiotics and skin-based research;
the challenges and opportunities in translating research towards commercialisation, and partnerships andcollaborations that secure investment. With 3 conferences and 8 tracks focusing on the topics below, there is
ample content to learn from top scientists, network and broaden your connections and should you wish showcase
your work in the poster presentation sessions or get involved in the interactive panel and roundtable discussions.

Microbiome & Probiotics R&D and Business Collaboration Forum

Skin &
Cosmeceuticals Congress

Room 1Room 2

Room 3

Room 4Day 1

Gut Microbiota for Health &Disease & Drug Development

Gut-Brain Axis

Infant Health,
HMO & Nutrition

Skin Microbiome& Cosmeceuticals

Day 2

Investment, Regulations& Manufacture

Women’s Health& Urobiome

Probiotics, Personalised
Nutrition & Cardiometabolic
Diseases

Skin Microbiome& Cosmeceuticals•

75 strong senior level speaker faculty•

Expert-led roundtables and interactive panel sessions•

Two 50-minute start-up flash presentation sessions•

Unique academic and industry joint focus•

Over 7 hours of networking time•

A fantastic reputation as the number one microbiome scientific & networking event.

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

OPEN LETTER

I am pleased to support the upcoming Microbiome R&D and Business Collaboration Congress in
San Diego this October.
Advances in the last few years have provided a much deeper understanding of the complex and dynamic microbialcommunities that inhabit our bodies and impact our health. High-throughput sequencing and bioinformatics havefacilitated more detailed and accurate analyses of microbial communities, revolutionizing our approach to microbiome
research. We now know that the microbiome affects everything from mucosal and systemic immune function to mental
health and chronic diseases.
Research has led to the creation of targeted live biotherapeutic products to optimize the vaginal microbiome toimprove reproductive health outcomes. Yet completing the development process to receive FDA approval has proved
challenging. However, clinical trials are taking place and are showing promise for the treatment of bacterial vaginosis
and the prevention of preterm birth. In addition, clinical trials of live biotherapeutics have demonstrated efficacy to treat
IBS, a range of skin conditions and improve infant health.
I’ll be giving the opening keynote on the potential of live biotherapeutic products to improve vaginal health. Bacterial
vaginosis is a common issue with high recurrence rates, but a live biotherapeutic, Lactobacillus crispatus (LACTIN-V), is
showing promise in reducing BV and inflammation associated with HIV susceptibility.
The advances are exciting, but we must continue studying these treatments to ensure long-term benefits. I look forward
to our discussions at the congress on how we can accelerate the advancement of live biotherapeutics to improve
reproductive health!

Craig R. Cohen
Professor, Department of Obstetrics, Gynaecology & Reproductive Sciences, University of California, San Francisco

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

EVENT SPONSORS

Platinum Sponsor

Gold Sponsor

Silver Sponsors

Other Sponsors & Exhibitors

SPONSORSHIP & EXHIBITION OPPORTUNITIES AVAILABLE
For more details contact Gavin Hambrook: gavin@globalengage.co.uk

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

MICROBIOME & PROBIOTIC SPEAKERSDAVID A. MILLSDistinguished Professor, Peter J. Shields
Endowed Chair in Dairy Food Science,
Department of Food Science andTechnology, University of California-Davis
HAYDEH PAYAMI
Professor of Neurology and Genomics,
Strain Endowed Chair in Parkinson’s
Disease, University of Alabama at
Birmingham
SENIOR REPRESENTATIVE
Biose Industrie
AMIR ZARRINPAR
Chief Medical Officer and Co-Founder,
Endure Biotherapeutics
BRADEN TIERNEY
Instructor, Weill Cornell Medical College /Harvard Medical School

REBECCA VONGSA
Technical Leader, Life Sciences, Kimberly
Clark Corporation

AMY SMITH
Director, Global Regulatory Affairs Health, IFF

PAUL CARLSON
Principal Investigator, Laboratoryof Mucosal Pathogens and Cellular
Immunology, CBER, FDA

JASON BUSH
Chief Scientific Officer, Solnul

LAURIE REY
Head of CDMO Business Development,
Lallemand
RYAN GARRETT
Head of Process Development, Vedanta
Biosciences
AMANDA L. LEWIS
Professor, Obstetrics, Gynecology, andReproductive Sciences, UCSDHANA JANEBDAR
Co-Founder & CEO, Juno Bio

SE JIN SONG
Director of Research, Applications for
Microbiome Innovation, UCSDJOHANNA MAUKONEN
Global Director, Clinical Innovation &Translation, IFF
JONATHAN SCHEIMAN
Founder & CEO, FitBiomics
CRISTINA LLORENTE
Assistant Professor, Div. Gastroenterology,
Dept. Medicine, UC San Diego
AUBREY LEVITTCEO, Postbiotics Plus Research LLC

ALEXANDRA CASTILLO-RUIZ
Assistant Professor, Michigan State
University

OLIVER WORSLEYCEO & Co-Founder, Sequential

ZAC LEWIS
Principal, Lewpine Consulting

LAURA SYCURO
Associate Profesor, University of Calgary

XIN ZHOU
Research Scientist, Snyder Lab, Stanford

ALEX SAKATOS
Co-Founder & CEO, Ancilia Biosciences

NOEL MUELLER
Associate Professor, University of Colorado
Department of Pediatrics and Johns
Hopkins Bloomberg School of Public Health

NOELLE PATNO
Chief Scientific Officer, Bened Life

CECILE VERNOCHET
Discovery Project Lead, Gates Medical
Research Institute

SATHYA JANARDHANAN
Vice President of Development &Manufacturing, Rise Therapeutics

JUN SUN
Professor/Associate Head, Department ofMedicine, University of Illinois Chicago

KIMBERLEY SUKHUM
Head of Science, Tiny Health

ALEX MARTINEZ
CEO and Co-Founder, Intrinsic Medicine

GIULIO M PASINETTIThe Saunders Family Chair in Neurology,
Professor in Neurology, Professor of
Psychiatry, Professor of Geriatric andAdult Development Director, Icahn Schoolof Medicine at Mount Sinai and JJ Peters
Bronx VA Medical Center

SENIOR REPRESENTATIVE
Cryptobiotix

ETHAN THAI
Microbiome Service Operation Manager,
Zymo Research Corporation

PEDRO J. TORRES
Principal Scientist, Computational
Biology and Data Science, Persephone
BiosciencesSYLVIE BINDA
R&D Vice President, Lallemand Health
SolutionsCARLOTTA RONDA
Principal Investigator, Innovative Genomics
Institute at UC Berkeley
JAMES MORTON
Consultant, Simons Foundation
DENISE KELLY
Investment Advisor, Seventure Partners
ALAN MURRAY
Chairman, Lactalogics
BHARAT DIXIT
Chief Technology Officer,
Adiso Therapeutics
CRAIG R. COHEN
Professor, Department of Obstetrics,
Gynaecology & Reproductive Sciences,
University of California San Francisco
CASSANDRA ISLEY
Chief Executive Officer, Microbiome
Alliance for Disease Prevention
KRYSTAL THOMAS-WHITE
Senior Scientist Evvy

JESSICA O’CONNELL
Partner, Covington & Burling LLPJUN DENG
Investment Partner, Joyance Partners

BRUNO BALEN
Co-founder, Ani Biome

REN-HAU LAI
Director of Innovation and ProductDevelopment, Athletic Greens
STEPHANIE FRALEY
Associate Professor
Shu Chien-Gene Lay Dept of
Bioengineering, UCSD
CHERYL SEW HOY
CEO & Founder, Tiny Health
LEILA STRIKLAND
CEO & Co-Founder, BIOMILQAMBER TEUFEL
Group Head/Microbiologist, Baby,
Feminine, and Family Care R&D Life
Sciences Division, Procter & Gamble
NOAH ZIMMERMAN
Chief Technology Officer, Verb Biotics

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

SKIN MICROBIOME SPEAKERSJULIA DURACK
VP of R&PD, Symbiome; Director,
Holobiont Medical Research Foundation

LADA RASOCHOVA
CEO, Dermala

ERIC (CHUN MING) HUANG
Professor, Arizona State University, USA

CHERI ACKERMAN
Co-Founder & CEO, Concerto
Biosciences

BRENT RIDGE
Co-Founder, Beekman1802

ANGELA CHRISTIANO
Professor of Genetics & Development,
Columbia University

KERA NYEMB-DIOP
Lead Nutritionist, Fonterra

ANDREA NARDELLI
Post-Doctoral Fellow McMaster
University- Farncombe Family Digestive
Health Research Institute

PING HU
R&D Director, Principal Scientist, Research& Development, Procter & Gamble

NATALISE ROBINSON
Co-Founder, Parallel Health
TIINA MEDER
CEO & Founder, Meder Beauty
BRADLEY RINGEISEN
Executive Director, Innovative Genomics
Institute (IGI)

FERANMI ABODERIN
Scientist I, Arcaea

ELSA JUNGMAN
Founder & CEO, HelloBiome

NICOLE SCOTTFounder & CEO, Cybele
JOSH PARRIS
Senior Scientist, Life Sciences,
Kimberly Clark Corporation

VENUE INFORMATIONSAN DIEGO MARRIOTT LA JOLLA
4240 La Jolla Village
La Jolla
CA 92037
www.marriott.com/en-us/hotels/sanlj-san-diego-marriott-la-jolla
La Jolla hotel's location is perfect, in San Diego's Golden Triangle.
The hotel offers convienient access to the University of California
at San Diego Scripps Research Institute and La Jolla Shores.

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 1 THURSDAY OCTOBER 17TH 2024

8:00-8:50

La Jolla Ballroom ABCD

8:50-9:00

Global Engage Welcome Address

Registration & Refreshments

La Jolla Ballroom – Salon E

La Jolla Ballroom – Salon H

MICROBIOME R&D & BUSINESS COLLABORATION FORUM

SKIN MIROBIOME & COSMECEUTICALS CONGRESS
Chair: Andrea Nardelli, Post-Doctoral Fellow McMaster University- Farncombe Family Digestive
Health Research Institute

Chair: Ren-Hau Lai, Director of Innovation and Product Development, Athletic Greens

KEYNOTE ADDRESS:DAVID A. MILLS

Co-Founder and Chief Scientific Officer, Dermbiont
Skin Microbiome Case Study

9:00-9:45

9:00-9:45

Distinguished Professor, Peter J. Shields Endowed Chair in Dairy Food Science, Department ofFood Science and Technology, University of California-Davis
The milk-enriched infant gut microbiome drives functional capacity during both breast feeding
and weaning
Milk directs the enrichment of the neonatal gut microbiome, an assembled “organ” with importantconsequences on host health. A prominent feature of human milk is an array of glycans that enrich a
protective microbiota often dominated by bifidobacteria. This milk-enriched gut microbiome naturallytransforms upon the consumption of solid foods resulting in a rearrangement of gut taxa and associatedfunctions. Recently, we have identified how specific milk glycans induce expression of genes that promote
growth on plant polysaccharides among select bifidobacteria, suggesting that milk also prepares gut taxa
for the weaning transition. Moreover, advances in new glycomics tools and databases, including the Davis
Food Glycopedia, are increasing our understanding of complex polysaccharides in weaning foods and theircatabolism by the infant gut microbiota. Analysis of these natural process will shed light on dietary andprobiotic tools to promote a protective gut microbiota for at-risk neonates from birth through weaning.

KEYNOTE ADDRESS:ROBERT BRUCKER (Reserved)

KEYNOTE ADDRESS:HAYDEH PAYAMIJULIA DURACK

10:20-10:50

10:20-10:50

SENIOR REPRESENTATIVE
Biose Indutrie

10:50-11:40

La Jolla Ballroom ABCD

VP of R&PD, Symbiome; Director, Holobiont Medical Research Foundation
Expanding the population demographic in microbiome studies challenges our prevailingconcepts of a healthy adult skin microbiome• The importance of improving understanding of skin microbiomes from around the globe• Lessons from broadening the population demographic in microbiome studies• Applying these findings to facilitate product development.

9:45-10:20

9:45-10:20

Professor of Neurology and Genomics, Strain Endowed Chair in Parkinson’s Disease, Universityof Alabama at Birmingham
Changing the landscape of Parkinson’s disease
90 disease-associated genes and numerous well-established environmental risk factors could not explain
PD. First emerging in 2015, microbiome studies have since shed new lights on the PD landscape, unearthed
new players in PD pathogenesis, and provided new targets for treatment.

30-Minute Solution Provider Presentation
For sponsorship opportunities contact Gavin Hambrookgavin@globalengage.co.uk

Morning Refreshments / One-to-One Partner Meetings / Poster Presentations

La Jolla Ballroom – Salon E

La Jolla Ballroom – Salon F

La Jolla Ballroom – Salon G

La Jolla Ballroom – Salon H

GUT MICROBIOTA FOR HEALTH & DISEASE

GUT-BRAIN AXISINFANT HEALTH, HMO & NUTRITION

SKIN MICROBIOME & COSMECEUTICALS

Chair: Ren-Hau Lai, Director of Innovation
and Product Development, Athletic Greens

Chair: Jun Sun, Professor/Associate Head,
Department of Medicine, University of
Illinois Chicago

Chair: Noel Mueller, Associate Professor of
Epidemiology, Johns Hopkins Bloomberg Schoolof Public Health

Chair: Andrea Nardelli, Post-Doctoral Fellow
McMaster University- Farncombe Family
Digestive Health Research Institute

CECILE VERNOCHETCHERI ACKERMANAMIR ZARRINPAR

GIULIO M PASINETTI

Discovery Project Lead, Gates
Medical Research Institute
Bifidobacterium longum ssp
infantis to Support Weight Gainin Underweight Infants in the
LMIC Setting
Undernutrition claims over 3 million children
annually, with 45% of under-5 deaths attributed toit, mostly in LMICs (WHO, 2021). Gut microbiomechanges are linked to childhood malnutrition

11:40-12:05

The Saunders Family Chair in
Neurology, Professor in Neurology,
Professor of Psychiatry, Professorof Geriatric and Adult Development
Director, Icahn School of Medicine at Mount Sinai
and JJ Peters Bronx VA Medical Center
Role of the Immune T Regulatory Cells in Mood
Disorders and Alzheimer’s Disease Phenotype
as a therapeutic target in Altered Gut-brain Axis
cross-talking

11:40-12:05

11:40-12:05

11:40-12:05

Associate Professor, Division of
Gastroenterology, University ofCalifornia, San Diego
The Therapeutic Potential ofEngineered Native Bacteria
We present pioneering research focusing onfunctional manipulation of the gut microbiomewith engineered native bacteria. This innovative
approach is licensed by Endure Biotherapeutics.
By engineering bacteria native to the luminal

Co-Founder & CEO, Concerto
Biosciences
Advances in a microbial ensemble
for atopic dermatitis• Concerto used its proprietary kChip technology
to map the skin microbe interactome andidentify Ensemble No.2 (ENS-002), a microbial
ensemble that prevents the bacterium S. aureus
from overgrowing and secreting toxins, anunderlying cause of atopic dermatitis.

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

ALEXANDRA CASTILLO-RUIZ

KIMBERLEY SUKHUM

Head of Science, Tiny Health
Tracking probiotic strains
across the infant and child gut
microbiome• The first 1,000 days of life are critical for
immune training. Infants with gut microbiome
imbalances are at elevated risk of atopic
disease including eczema and food allergies.
Early action can shift microbiome compositionand lower disease risk. The Tiny Health gut
microbiome test empowers parents to takethose early actions through personalizedrecommendations.
• The new Tiny Health Strain Tracker can trackprobiotic strain colonization and efficacy inremodeling the infant gut, characterize straintransfer from mother to infant, identify strain
sharing between family members, and validate
probiotic formulations at the strain level.
• This tool has enabled us to characterize
probiotic strain presence across a width
breadth of samples including unique disease
conditions, diet, and other variables. We
envision a future in which personalized gut
microbiome care is the clinical standard.

KERA NYEMB-DIOP

Lead Nutritionist, Fonterra
Skin Microbiome Case StudySENIOR REPRESENTATIVEETHAN THAI

Cryptobiotix

12:30-12:45

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

12:30-12:45

12:30-1:30

12:30-1:00

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk• Learn about the kChip discovery technologythat reveals the ecological underpinnings ofthe microbiome, thereby enabling the design ofdefined microbe-based interventions to benefit
human health.
• Hear the latest update on ENS-002's
manufacturing and first-in-human dose
escalation trial.

12:05-12:30

Assistant Professor, Michigan
State University
The maternal microbiota programs
brain development in mice:a potential role for bacterial
metabolites
Mammals experience a massive colonization by
microorganisms at birth. We previously reported
that germ-free (GF) newborn mice have alteredbrain development, including increased cell
death in the hypothalamus. To test whether theseeffects are due to postnatal microbial exposure, or
programmed in utero by the maternal microbiota,
we cross-fostered GF newborns immediately
after birth to conventionally colonized (CC)mothers, and collected their brains a week
later. Interestingly, the GF brain phenotype
largely persisted despite a normal microbiota,
suggesting programing effects of the maternal
microbiota. To probe for mechanism, we treatedpregnant CC mice with bacterial metabolites
and collected offspring during the first threedays postnatal. We found that treatment
reduced cell death in the hypothalamus. Thus,
maternal bacterial metabolites may be importantneurodevelopmental agents.

12:05-12:30

12:05-12:30

12:05-12:30

Instructor, Weill Cornell Medical
College /Harvard Medical School
Leveraging multi-omic data science
to build the next-generation of
microbial-based therapies
The next generation of microbial therapeutics(e.g., probiotics) will look nothing like what we seeon shelves now. Generally, the organisms usedin therapy development have been limited to atiny window of the tree of life, comprising easily
cultured and well-characterized species, withlimited consideration for strain-level variation.
The perhaps “best” strains for treating a given
phenotype were either not known or not practicalfrom a productization cost standpoint. However,three simultaneous advances will in the next
decade flip this paradigm, allowing for the creationof functionally-driven, strain-specific microbial
therapeutics. These are 1) multi-omic data science(e.g., DNA sequencing and metabolomics at massive
scale), 2) high-throughput, high-volume culturomics,
and 3) increasingly large human clinical cohorts withpaired microbiome sequencing information. The
union of these tools will enable the commercializationof microbial therapies that are directly built basedon their relationship to specific human diseases andsubpopulations. Here, I will discuss where to look forbellwethers in academic research signaling theseadvances, both in my work and the broader field, with
an emphasis on the complex interplay between dietand gut microbiome interactions.

and intestinal inflammation risk (Kane 2015).
A healthy infant gut, rich in Lactobacillus andBifidobacterium, supports vital functions likeimmune system development and resistance topathogens. Gates MRI is conducting clinical trials
investigating the potential of Bifidobacterium
longum ssp infantis probiotic products to support
weight gain in infants being treated for severe
acute malnutrition. In addition, we are comparing
mechanism of action and efficacy in preclinicalmodels of commercial B.infantis probiotic strains.

11:40-12:05

BRADEN TIERNEY

The role of the gut-brain axis in the onset andprogression of degenerative conditions, including
Alzheimer’s disease, will be discussed. In particular,
the implication of the causative role of T-regulatory
cells mediated influence on adaptive immunity inthe gut-brain axis communication. Discussion ofstrategies to intervene in the brain degenerative
progression by targeting selected T-regulatory
mediated mechanisms to mitigate abnormal brain
permeability and disease progression in responseto stress-induced mood/ psychological impairment
associated with the onset of Alzheimer’s diseasephenotype. Discussion of novel strategies to movefrom preclinical observations to the clinical setting.

11:40-12:05

11:40-12:05

11:40-12:05

environment, we developed a technique to introduce
specific functions into the gut, effectively changing
physiology in conventional hosts and ameliorating
chronic diseases with a single intervention in
preclinical models. We present studies where wehave used this intervention on preventing colorectal
cancer in a mouse model of familial adenomatous
polyposis, treating severe colitis in an animal modelof inflammatory bowel disease, improving glucose
homeostasis in a type 2 diabetes model, andimproving health span in aged mice. This researchpromises significant therapeutic potential, offering
new strategies for disease prevention and treatment.

DAY 1 THURSDAY OCTOBER 17TH 2024

Microbiome Service
Operation Manager,
Zymo Research Corporation
What 100 Femtograms of DNA
Can Reveal with Shotgun Metagenomics
Sequencing
Zymo Research's recent breakthroughs in shotgun
metagenomics have enabled researchers togain comprehensive insights into microbiomes
with DNA inputs as low as 100 femtograms.
This capability allows for enhanced taxonomic
resolution and functional pathway analysis,
providing a more detailed understanding of

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 1 THURSDAY OCTOBER 17TH 2024

12:45-13:00

La Jolla Ballroom ABCD

15-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

Continued

12:45-1:00

1:00-2:00

12:30-12:45

12:30-12:45

12:30-1:30

12:30-1:00

Continued

Continued

microbial communities. By reducing the amountof DNA required, we can explore diverse
environments and conditions, such as extreme
habitats and clinical settings, where sample
availability is limited. This advancement facilitates
unbiased profiling and deeper exploration of
microbial interactions and dynamics, leading tosignificant implications for health, agriculture, andenvironmental science. In this talk, we will examine
how these developments open new avenues for
microbiome research, enabling us to addresscomplex biological questions and drive innovation

15-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

Lunch / One-to-One Partner Meetings

GUT MICROBIOTA FOR HEALTH & DISEASE

INFANT HEALTH, HMO & NUTRITION

SKIN MICROBIOME & COSMECEUTICALS

Chair: Jan Claesen, Assistant Professor,
Department of Cardiovascular and Metabolic
Sciences, Cleveland Clinic Lerner Collegeof Medicine

Chair: Sylvie Binda, Vice-President R&D,
Lallemand

Chair: Stephanie Fraley, Associate
Professor, Shu Chien-Gene Lay Dept of
Bioengineering, UCSD

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

XIN ZHOU

NOELLE PATNO

Chief Scientific Officer, Bened Life
Trials To Testimonials: A Probiotic
for Autism
Multiple trials have demonstrated thatprobiotic PS128 benefits Autistic children, but what
about Autistic adults? Through three randomized,
double-blind, placebo-controlled trials and one realworld study, Lactiplantibacillus plantarum PS128
addressed anxiety and other behaviors in autistic
children, enrolling people younger than 20. This
talk will review the evidence of how PS128 provides
benefits in autism and show lessons learned fromthe field through analysis of customers’ satisfaction
with the product containing PS128.

No Track Talk

PEDRO J. TORRES

2:30-2:55

2:30-2:55

2:30-2:55

Research Scientist, Snyder Lab,
Stanford
Longitudinal profiling of the
microbiome at four body sites
reveals core stability andindividualized dynamics during
health and disease• Human microbiomes from different body sites
are highly individualized and stable over time.
• Coordinated microbial dynamics between bodysites are observed in response to disease• Besides Gut microbiome, Skin microbial
composition and stability are also altered withinsulin resistance

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

2:30-2:55

La Jolla Ballroom – Salon H

2:00-2:30

La Jolla Ballroom – Salon G

GUT-BRAIN AXIS

2:00-2:30

La Jolla Ballroom – Salon F

2:00-2:30

2:00-2:30

La Jolla Ballroom – Salon E

Principal Scientist, Computational
Biology and Data Science,
Persephone Biosciences
My Baby Biome Study: A DataDriven Approach to Infant Probiotic Development
The infant microbiome plays a crucial rolein establishing a healthy host-microbiome
relationship. Recent research has identified acritical window in early-life (the first 3 months)
where gut microbial dysbiosis has the mostimpact on human immune development. Existing
infant microbiome datasets lack comprehensive
multi-omics analysis and sufficient racial andethnic diversity for population-wide biomarker
discovery. Persephone Biosciences addressed
this gap through the My Baby Biome (MBB)
study, enrolled ~700 infants up to the age of
3 months across the U.S, representative of
US birth and feeding modes Using shotgun
metagenomic sequencing and metabolomics,
we identified three microbiome compositional
clusters. A healthy cluster was distinguishedby high Bifidobacterium levels and association
with specific anti-inflammatory metabolites.
Further exploration of MBB isolated strains and

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 1 THURSDAY OCTOBER 17TH 2024

Poster presenters and start-up companies will
be provided with the opportunity to give a flash
3-minute overview of their work
Full list of talks shown at the end of day 1.

2:55-3:20

Paving the way to clinical validity and improving
health outcomes in the microbiome industry

NATALISE ROBINSON (Chair)

Co-Founder, Parallel HealthRoundtable 1:

TIINA MEDERJESSICA O’CONNELL

CEO & Founder, Meder Beauty

Partner, Covington & Burling LLP
Probiotics Claims and IP
Roundtable 2:

BRADLEY RINGEISEN

REN-HAU LAI

Director of Innovation and ProductDevelopment, Athletic Greens
The challenge of probiotic productdevelopment and the future

Executive Director, Innovative
Genomics Institute (IGI)

Roundtable 3:

CEO, Dermala

LADA RASOCHOVASTEPHANIE FRALEY

Associate Professor, Shu Chien-GeneLay Dept of Bioengineering, UCSD
Antibiotics and Infant healthRoundtable 4:

CHERYL SEW HOY

CEO & Founder, Tiny Health
New discoveries leveraging
at-home microbiome profilingand probiotic strain tracking via
shotgun metagenomics

2:55-3:45

3:20-3:45

CEO and Co-Founder, Intrinsic
Medicine
A Prebiotic Approach to Treat Gut
Immune Microbiome Brain Axis
Disorders (GIMBADs)
Mounting evidence implicates the complex
interaction between the gut microbes, immune
system, and central nervous system in a numberof severe and chronic conditions including
Parkinson’s disease, Autism Spectrum Disorders(ASD) and Alzheimer’s disease suggesting they
be evaluated as Gut-Immune-Microbiome-BrainAxis Disorders (GIMBADs). Prebiotics are key inmodulating this axis; among these, Human Milk
Oligosaccharides (HMOs) stand out for theirunique ability to selectively nourish beneficial
gut bacteria, inhibit pathogenic bacteria, andmodulate the immune and nervous systems.
These non-digestible carbohydrates have a
proven safety profile, and have been shown to
impact neuroinflammation and neurotransmitter
production both critical in the pathology ofdisorders such as Parkinson’s disease. By focusing
on the therapeutic potential of HMOs, we canleverage compounds fundamental to humandevelopment to address neurodegenerative
diseases, as well as other GIMBADs.

Continued

PANEL DISCUSSION

Roundtables are informal, small-group interactive
discussions on key topics in the field. Discussion
leaders will introduce sub-topics/questions
for discussion and roundtable attendees areencouraged to participate actively in the session.

2:55-3:45

2:55-3:45
La Jolla Ballroom ABCDCROSS-EVENT ROUNDTABLES SESSION ONE

Professor/Associate Head,
Department of Medicine, University
of Illinois Chicago
Microbiome and metabolite
regulate the progression of ALS
through the gut-brain axis
Amyotrophic lateral sclerosis is aneurodegenerative disorder. Despite extensive
studies, it remains challenging to treat ALS.
Recent ALS studies have shown dysbiosis iscorrelated with intestinal inflammation andchange of intestinal integrity in ALS. The
novel concepts and the roles of microbiome
and microbial metabolites through the gutmicrobiome-neuron axis in ALS pathogenesis
have been slowly recognized by the neurology
research field. Here, we will discuss our new data
and understanding of microbial metabolites in
reducing TDP43 aggregation and inflammationin ALS. We propose that the mechanistic andtranslational studies that shift from suspensionof disbelief to cogent ingenuity, and from bench
study to bed-side application, should allow new
strategies of diagnosis and treatment for ALS.

ALEX MARTINEZ

2:30-2:55

JUN SUNPOSTER PRESENTATION FLASHPRESENTATIONS & START-UP
SHOWCASE PRESENTATIONS

3:45-4:35

Continued

2:30-2:55

2:30-2:55

2:30-2:55

Continued

commercial strains in ex-vivo gut environments
revealed their impact on microbial composition
and function. These findings provide a datadriven approach to infant probiotic development.

Full details shown on page 17

Afternoon Refreshments / One-to-One Partner Meetings / Odd Numbered Poster Presentations

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

MALCOLM KENDALL (Chair)
Co-Founder & CEO, Microbiome
Insights, Inc., Canada
DENISE KELLY

Investment Advisor, SeventurePartners

CEO and founder ,Meder by Dr Tiina Meder
Sensitive skin microbiome: latest
findings and clinical cases.
• The relationship between skin microbiome
and sensitivity remains unclear, but a newconsensus suggests a balanced interplay
between skin cells and bacterial populations
maintains healthy skin barrier integrity.
• Recent findings indicate a unique sensitive
skin microbiome has lower diversity andreduced S. epidermidis compared to nonsensitive skin. This can be particularly relevant
for individuals with compromised skin barriers,
such as those with sensitive, reactive skin, or
those suffering from allergies or dermatosis
such as acne, rosacea.
• Cosmeceutical ingredients that increase an
amount of free water in the Stratum Corneum,along with prebiotics promoting S. epidermidis
growth and suppressing C. acnes or P. ovale,
show therapeutic potential. Clinical cases
using skincare with prebiotics and symbiotic
ingredients in sensitive skin demonstrateefficacy, offering insights for dermatologists
and public recommendations.

BRENT RIDGE

5:30-5:55

Associate Professor of Epidemiology,
Johns
Infant Health, HMO & Nutrition
Case Study
Determinants, health consequences, andrestoration of key features of the infant gut
microbiome• Mother-infant sharing of vaginal and gut
microbes, including B. infantis and otherbifidobacteria• Factors that impact mother-infant sharing of
microbes• Associations of infant microbiota featureswith cardiometabolic health and themodifying role of breastfeeding• Restoration of the infant microbiota
by vaginal seeding and its effects on
cardiometabolic outcomes

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

TIINA ORASMÄE-MEDERNOEL MUELLER

5:30-5:55

Investment Partner, Joyance Partners

5:30-5:55

5:30-6:20

JUN DENG

Chief Technology Officer,
Adiso Therapeutics
Development of a SS-LBP,
ADS024, for the treatment of PD
Over the years, evidence for a close link
between the gut and brain (gut-brain axis) has
been mounting, leading to a paradigm shift inthe understanding of diseases involving thenervous system, including Parkinson disease(PD) and multiple sclerosis (MS), to namea few. It has been recognized that somemicrobes in the gut modulate the production ofseveral metabolites that have neuromodulatory
functions and signal via the vagus nerve andthe circulation. ADS024 is a single-strain live
biotherapeutic (SS-LBP) that can impact thenervous system via its unique properties andis currently being studied for the treatment of
Parkinson disease.

CEO & Co-Founder, BIOMILQBIOMILQ on expanding thepossibilities for HMOs withmammary-based biomanufacturing
Of the ~200 known HMO structures, less than
10% can be produced commercially today.
BIOMILQ is building a novel, patented process
to unlock the other 90% by leveraging theunique capability of human mammary epithelial
cells (hMECs). Due to the complex enzymatic
pathways involved in HMO production – achallenge that has held the field back for overa decade – hMECs may be the only feasible
platform to produce structurally complex HMOs.
BIOMILQ is at the forefront of building a system
to produce a complex mixture of HMOs that
support infant gut, immune, and brain health, in
addition to other applications for improving healthacross the lifespan.

5:05-5:30

BHARAT DIXITThe Shifting Winds of Microbiome Investment

Chairman, Lactalogics

Consultant, Simons Foundation
Multi-level analysis of the gut–brain axis shows autism spectrum
disorder-associated molecular andmicrobial profiles
Autism spectrum disorder (ASD) is aneurodevelopmental disorder characterized
by heterogeneous cognitive, behavioral andcommunication impairments. Disruption of
the gut–brain axis (GBA) has been implicatedin ASD although with limited reproducibility
across studies. Here, we developed a Bayesiandifferential ranking algorithm to identify ASDassociated molecular and taxa profiles across
10 cross-sectional microbiome datasets and
15 other datasets, including dietary patterns,
metabolomics, cytokine profiles and human brain
gene expression profiles. We found a functionalarchitecture along the GBA that correlates withheterogeneity of ASD phenotypes, and it ischaracterized by ASD-associated amino acid,carbohydrate and lipid profiles predominantly
encoded by multiple microbial species andcorrelates with brain gene expression changes,
restrictive dietary patterns and pro-inflammatory
cytokine profiles. We also show a strong
association between temporal changes in
microbiome composition and ASD phenotypes in
the context of a fecal matter transplant.

5:05-5:30

5:05-5:30

5:05-5:30

PANEL DISCUSSION

ALAN MURRAY

LEILA STRIKLANDJAMES MORTON

Principal Investigator, Innovative
Genomics Institute at UC Berkeley
Targeted microbiome engineering• In vivo Microbiome Engineering• Human-Microbiome interactions• Microbiome-based Therapeutics

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

4:35-5:05

CARLOTTA RONDA

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

4:35-5:05

4:35-5:05

4:35-5:05

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

DAY 1 THURSDAY OCTOBER 17TH 2024

Co-Founder, Beekman1802
The Science of Kindness
Beekman 1802 is a skin healthcompany with two key ingredients:
goat milk and Kindness and is one of the fastest
growing beauty companies in America. Learn
their approach to product development andconsumer education around the microbiome. An
insightful discussion of how the research you
are conducting now gets into the hands of theconsumer of the future.

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 1 THURSDAY OCTOBER 17TH 2024
BRUNO BALENAMBER TEUFEL

Group Head/Microbiologist, Baby,
Feminine, and Family Care R&D Life
Sciences Division, Procter & Gamble
What’s bugging your baby’s skin?:insights from healthy and diaper
dermatitis skin
It has been recognized for nearly a century thathuman beings are inhabited by a remarkably
dense and diverse microbial ecosystem, yet we are
only just beginning to understand and appreciate
the many roles that these microbes play in humanhealth and development. Previous studies on infantskin health has focused on Candida species but
little is known on the full microbial composition
across different areas and even less is known on
how these communities change during disease/inflammatory states. This clinical trial revealed
to us distinct communities that exist across 4
different regions of the diapered area as well
as demonstrated trends in how the populations
change from healthy skin to disease state. We will
discuss these microbial communities and what theindications are for understanding the roles it plays
in disease states like diaper dermatitis (DD).

ANDREA NARDELLI

5:55-6:20

5:55-6:20

6:20

5:55-6:20

5:30-6:20

Continued

Co-founder, Ani Biome
Decoding the Longevity Algorithm:
AI-Driven Modulation of the GutImmune-Brain Axis
• AI-Driven Insights: Development of advanced
machine learning algorithms to decode complex
interactions within the gut-immune-brain axis,
facilitating predictive modeling and biomarker
discovery• Personalized Therapies: Utilization of AI for
creating clinically validated, personalizedcompounds (AgeBiotics) as adjunct therapies,
tailored through longitudinal multispectral
diagnostics• Gut-Brain Modulation: Elucidation of thedirect dialog between gut microbiota andbrain function, impacting cognitive capacity,
emotional flexibility, and immune system health• Longevity Algorithm: Introduction of theconcept that future longevity interventions
may not be single molecules, but algorithms
integrating multiple stimuli, including medicine
and nutraceuticals

Post-Doctoral Fellow McMaster
University- Farncombe Family
Digestive Health Research Institute
Skin dysbiosis as acomplication of biologics andimmunosuppressant agents use:challenges and future directions
Description of Skin lesions in patients treatedwith immunosuppressant and other biologicalagents, such as atopic dermatitis, sensitive
skin, psoriasiform eczema, and acneiform
dermatitis; presentation of complex clinicalpictures. The consideration arises whether skindysbiosis contributes to the pathophysiologyof these manifestations as complications of
immunosuppressant agent use. The potential
impact of therapeutic manipulation of skinmicrobial communities, including the use of preand probiotics, emerges as an intriguing avenue
to explore in efforts to maintain skin health.

Drinks Reception / End of Day 1

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 2 FRIDAY OCTOBER 18TH 2024

8:00-8:55

La Jolla Ballroom ABCD

8:55-9:00

Global Engage Welcome Address

Registration & Refreshments

La Jolla Ballroom – Salon E

La Jolla Ballroom – Salon H

MICROBIOME R&D & BUSINESS COLLABORATION FORUM

SKIN MICROBIOME & COSMECEUTICALS CONGRESS

Chair: Xin Zhou, Research Scientist, Snyder Lab, Stanford University of Medicine

KEYNOTE ADDRESS:CRAIG R. COHEN

Chair: Oliver Worsley, CEO, Sequential Skin

SENIOR REPRESENTATIVE (Reserved)

9:00-9:30

9:00-9:45

Invitation Out
Skin Microbiome Case StudyFERANMI ABODERIN

9:30-9:55

Professor, Department of Obstetrics, Gynaecology & Reproductive Sciences, University of California
San Francisco
The Potential of Live Biotherapeutic Products to Optimize the Vaginal Microbiome to
Improve Reproductive Health
Bacterial vaginosis (BV), a proinflammatory genital condition marked by high bacterial diversity anddiminished Lactobacillus species, is linked with increased HIV transmission risks and preterm birth.
BV is highly prevalent, with greater risk among African American and Hispanic women in the U.S. andin Africa. Antibiotic treatment of BV, though standard, faces high recurrence rates, possibly due to theinability to promote Lactobacillus growth. An innovative treatment strategy employing a live biotherapeutic
Lactobacillus crispatus (LACTIN-V) has shown promise optimizing the vaginal microbiome, reducing
recurrent BV, and mitigating the genital tract’s inflammatory milieu, thus decreasing HIV susceptibility.
Future studies are imperative to evaluate long-term BV treatments with live biotherapeutics that encouragecolonization with H2O2-producing vaginal lactobacilli.

Scientist I, Arcaea
Microbiome Modulation for Effective Odor Control
Traditionally, deodorants have used chemistry-based methods to prevent malodor, often
ignoring underlying biological factors and sometimes causing side effects like irritation, itch,and inflammation. Our research introduces a novel biology-first approach to personal care, aiming to control
axillary odor through skin microbiome modulation. By harnessing bioinformatics, machine learning, andhigh-throughput screening, we developed ingredients designed to produce desired microbiome shifts. These
ingredients were benchmarked in vitro for efficacy using metabolic assays and next-generation sequencing,and further validated in volunteer in-vivo trials, confirming microbial shifts and malodor prevention. Thisapproach demonstrates the effectiveness of microbiome modulation in managing axillary malodor.

KEYNOTE ADDRESS:CASSANDRA ISLEYNICOLE SCOTT

10:50-11:40

La Jolla Ballroom ABCD

10:20-10:50

10:20-10:50

30-Minute Solution Provider Presentation
For sponsorship opportunities contact Gavin Hambrookgavin@globalengage.co.uk

Founder & CEO, Cybele
Skin Microbiome Case Study

9:55-10:20

9:45-10:20

Chief Executive Officer, Microbiome Alliance for Disease Prevention
Microbiome Medicine: Combating Chronic Inflammatory Disease States
The gut microbiome’s influence on the immune system is profound and far-reaching. The gut
microbiota can modulate our immune responses, both in the gut and throughout the body. Incorporating
the critical components of immune health, metabolic health, and the health of the microbiome is essential inpreventing and combating chronic inflammatory disease states. The future of medicine is strongly related tothe quality of our gut microbiome and has profound implications for disease prevention.

30-Minute Solution Provider Presentation
For sponsorship opportunities contact Gavin Hambrookgavin@globalengage.co.uk

Morning Refreshments / One-to-One Partner Meetings / Poster Presentations

La Jolla Ballroom – Salon E

La Jolla Ballroom – Salon F

La Jolla Ballroom – Salon G

La Jolla Ballroom – Salon H

REGULATION AND MANUFACTURE

UROLOGY & WOMEN’S HEALTHPROBIOTICS, PERSONALIZED NUTRITION& CARDIOMETABOLIC DISEASESSKIN MICROBIOME & COSMECEUTICALS

Chair: Xin Zhou, Research Scientist,
Snyder Lab, Stanford University

Chair: Michael Hartman, Vice President ofResearch and Development, Plexus Worldwide

SYLVIE BINDA

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

11:40-12:10

Vice-President R&D,
Lallemand
Understanding the Microbiome
and the Influence of Probiotics in
Women’s Health Throughout Their Lives
Probiotic-supported modulation of the gut and11:40-12:10

11:40-12:10

11:40-12:10

30-Minute Solution Provider Presentation
For sponsorship opportunities contact
Gavin Hambrookgavin@globalengage.co.uk

PANEL DISCUSSION:ELSA JUNGMAN (Chair)

Founder & CEO, HelloBiome
AI and the Microbiome

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 2 FRIDAY OCTOBER 18TH 2024

Poster presenters and start-up companies will
be provided with the opportunity to give a flash
3-minute overview of their work.
Full list of talks shown at the end of day 1.

AMY SMITH

12:35-1:00

12:35-1:00

La Jolla Ballroom ABCD

Technical Leader, Life Sciences,
Kimberly Clark Corporation
Factors Influencing the Vulva skin
Microbiome and its Impact on
Feminine Wellness
A healthy vulvar microbiome is important part offeminine health. Disruption of the microbiome
balance in the vulva can contribute to infection,
discomfort, and irritation. Age, genetics, andhealth conditions can alter the vulvar microbiome.
Herein, the effect of age, body mass index,
and urinary incontinence have on the vulvar
microbiome will be discussed. Furthermore,principles to support a healthy vulvar microbiome
and importance of science informed guidelines
for vulvar hygiene will be presented.

Chief Technology Officer, Verb Biotics
Tailoring the microbiota to the dietfor targeted metabolite production
The diet provides a treasure troveof material for the production of bioactive
metabolites. Many of these metabolites are
generated by members of the microbiome.
However, a lack of either the right diet or
the right microbiome members can havea significant impact on the availability ofhealth promoting metabolites in the body.
Supplementation of probiotics that work
synergistically with the diet to produce targeted
metabolites through biotransformation, open
up the opportunity to enrich the nutritional andhealth benefits of the diet.

Director, Global Regulatory Affairs Health, IFF
Regulatory Strategy for Next
Generation Probiotics
Novel and next generation probiotics require“extra” regulatory know-how, concerning safety,
categorization and strategic marketing.

Roundtables are informal, small-group interactive
discussions on key topics in the field. Discussion
leaders will introduce sub-topics/questions
for discussion and roundtable attendees areencouraged to participate actively in the session.
Roundtable 1:

TIINA ORASMÄE-MEDER

CEO and founder , Meder by
Dr Tiina Meder
How to speak about a microbiome:
educational challenge in skincare
industry
Roundtable 2:

SATHYA JANARDHANAN
12:10-1:00

REBECCA VONGSA

Continued

CROSS-EVENT ROUNDTABLES SESSION TWONOAH ZIMMERMAN

12:10-12:35

12:10-12:35

12:10-1:00

Senior Scientist Evvy
The Vaginal Microbiome & DTC
Women’s Health
The vaginal microbiome is a criticalcomponent of female health. More than 30% of
people with vaginas suffer from imbalances in
the microbiome (e.g. bacterial vaginosis, yeast
infections, and recurrent UTIs) that drasticallyaffect our quality of life. Additionally, research
has uncovered groundbreaking links between
the vaginal microbiome and infertility, HIV risk,
preterm birth, gynecologic cancers, and more.
Evvy’s longitudinal, metagenomic testing is
unlocking personalized definitions of health anddisease in the vagina and providing women witheducation and insights about their vaginal healthalong the way. This talk will highlight how Evvy isleveraging the vaginal microbiome to positively
impact women’s health outcomes.

Continued

11:40-12:10

KRYSTAL THOMAS-WHITEPOSTER PRESENTATION FLASHPRESENTATIONS & START-UP
SHOWCASE PRESENTATIONS

1:00-2:00

11:40-12:10

11:40-12:10

11:40-12:10

Continued

vaginal microbiomes, two dynamic environmentswith significant impacts on women’s healthstatus, shows encouraging results to support
women’s health throughout their lives. A recent
study showed that probiotics could preserve
gastrointestinal function and alleviate somemenstrual symptoms during this uncomfortable
and stressful period. In other studies, we showedthat the perinatal use of probiotics in pregnant
women, who are more susceptible to infections,
could reduce infections and regulate microbiome
fluctuations, respectively. Moreover, due to the early
exposure to beneficial microbes through verticaltransfer during delivery and via breastfeeding,perinatal probiotic use by the mother exerted
positive effects on the newborn. Overall, ourrecent studies confirmed the promising effects ofprobiotics in the management of gastrointestinal
symptoms during menstruations, the maintenanceof a healthy pregnancy as well as beneficial effects
on the infant gut microbiome establishment.

VP, Manufacturing, Rise
Therapeutics
LBP Manufacturing TBC
Roundtable 3:

CRISTINA LLORENTE

Assistant Professor, Div.
Gastroenterology, Dept. Medicine,
UC San Diego
The Gut Microbiome's Impact on
Liver Disease: Exploring Novel
Therapies
Roundtable 4:

AUBREY LEVITTCEO, Postbiotics Plus Research LLC
Bioactive compounds and the gut
microbiome
Full details shown on page 17

Lunch / One-to-One Partner Meetings

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 2 FRIDAY OCTOBER 18TH 2024

La Jolla Ballroom – Salon E

La Jolla Ballroom – Salon F

La Jolla Ballroom – Salon G

La Jolla Ballroom – Salon H

GUT MICROBIOTA FOR HEALTH & DISEASEUROLOGY AND WOMEN'S HEALTHINFANT HEALTH, HMO & NUTRITION

SKIN MICROBIOME & COSMECEUTICALS

Chair: Ren-Hau Lai, Director of Innovation
and Product Development, Athletic Greens

Chair: Larry Weiss, Founder & CEO,
Symbiome

Chair: Bharat Dixit, Chief Technology Officer,
Adiso Therapeutics

50 MINUTE PANEL DISCUSSIONHANA JANEBDARPAUL CARLSON

Principal Investigator, Laboratoryof Mucosal Pathogens and Cellular
Immunology, CBER, FDA

SATHYA JANARDHANAN
VP, Manufacturing, Rise
Therapeutics

Biose

RYAN GARRETT

Head of Process Development,
Vedanta Biosciences

Director of Research Programs,
Center for Microbiome Innovation,
UC San Diego
From gradients to bins: taking steps
towards personalized nutrition
For both the gut microbiome and diet, the variation
across people on the globe is vast and exists ina gradient. Both are multi-dimensional and are
affected by and linked to numerous other factors.
All of these features make it difficult to achieve
truly personalized nutrition. However, we can work
towards this goal in steps by binning individuals
into more and more defined groups based on
patterns in their microbiomes and diet.

Senior Scientist, Life Sciences,
Kimberly Clark Corporation
The skin microbiome of preterm
infants and impact of diaper
change frequency
Development of the cutaneous microbiome isimportant to overall health during the neonatal
period and this may be especially true inpreterm infants who are more susceptible
to infection by opportunistic skin colonizers.
In this study, we describe diversity andcomposition and evaluate the impact of diaper
change frequency, clinical characteristics,
and skin health metrics on the preterm infantskin microbiome. For diapered skin, diaper
change frequency, diet, antibiotic exposure, anddelivery mode were all associated with variationin microbiome composition. Microbiome
diversity was inversely correlated with skinpH but not TEWL. Results presented here
provide important insights into the drivers of
microbiome development for preterm infants.

ERIC (CHUN MING) HUANG

2:25-2:50

SENIOR REPRESENTATIVEJOSH PARRISSE JIN SONG

2:25-2:50

Head of CDMO Business
Development, Lallemand

2:25-2:50

LAURIE REY

Co-Founder & CEO, Juno Bio
Vaginal Microbiome Testing:
Challenges and Opportunities
As the role of vaginal microbiome
testing in radically improving patient outcomes isincreasingly recognized, we map the trajectory,
challenges, and opportunities in this evolving
field. Key challenges from clinical integration tovariability of data for R&D are weighed against
the vast potential for personalized medicine andpreventative care with real-world examples from
Juno Bio's pioneering lab and customer base.

Chief Scientific Officer, Solnul
Metabolomic and microbiome
investigations in a prebiotic
resistant starch clinical
trial reveal novel pathways
influencing lipid metabolism
Resistant starch (RS) has long been appreciatedfor metabolic benefits at high doses (+30g/
day). We conducted the first low dose (3.5g/day) RS study and applied serum metabolomic
analysis to evaluate system effects due to theconsumption of this prebiotic. RS consumption
led to a significant and clinically meaningful
reduction in a non-glucose marker of insulin
sensitivity. The application of metabolomic
analysis in clinical trials, including study design,interpretation, and dietary supplement structure/function claims substantiation, will be discussed.

2:00-2:25

BHARAT DIXIT (Chair)Chief Technology Officer,
Adiso Therapeutics

Professor, Obstetrics, Gynecology,
and Reproductive Sciences, UCSD
Preclinical models forvalidation and quality controlof electrospun fibers and 3D
bio-printed scaffolds as vaginal
therapeutic delivery platforms
Current treatments for BV to restore a balanced
vaginal microbiome rely on frequent user
administration. There is a pressing need toquickly and more stably colonize the vagina withlactobacilli to avoid BV recurrence. Here, wevalidated a potential probiotic delivery devicein our mouse model. L. crispatus-loaded fibers
were placed into mouse vaginas with the goalof achieving colonization by L. crispatus without
eliciting inflammation or injury. Our experiments
show that vaginal colonization by L. crispatus canbe achieved by incorporating polymers that sustain
the release of live probiotics in the mouse vagina.

2:00-2:25

2:00-2:25

2:00-2:50

Key questions• What are the current major hurdles in LBP
manufacturing? Are we still struggling withcapacity and/or expertise• What are the latest developments and mostimportant advances in manufacturing of typicalvs highly sensitive strains?
o How can we leverage prior knowledge
developing difficult to grow/scale strains• Global regulatory convergence, What is thestatus of the Regulatory framework (US vs EU)
for production and registration of LBPs?
• The potency of the product and it’s effect, are
we still relying of CFU or something better?
• What are the main considerations regarding
internal vs external manufacturing?

JASON BUSH

AMANDA L. LEWISCurrent Challenges and Future Opportunities
in LBP Manufacturing• Identify and discuss the current major hurdles
in LBP manufacturing, key pain points• New analytical tools to support LBPcharacterization, release and stability• Weigh the pros and cons of internal versus
external manufacturing (single strain vsconsortia, strict vs facultative aerobe, aerobes)

Professor, Arizona State
University, USA
Redox (Electrogenic) Bacteriaas Biotherapeutics Against
Oxidative Stress
Reactive oxygen species (ROS), a subset of free
radicals, have been implicated in many humandiseases. Our results have demonstrated thatcarotenoid-carried skin and gut bacteria areelectrogenic and can yield electricity to rescue
the redox imbalance caused by oxidative
stress. Taking skin electrogenic bacteria for
instance, we found that topical application of
S. epidermidis plus glycerol on dorsal skin of
ICR mice significantly attenuated ultraviolet(UV)-elevated liable ferrous ions as well as
4-hydroxy-2-nonenal (4-HNE), a free radical
marker derived from lipid peroxidation.
Incubation of carotenoids enhances electricity
production of S. epidermidis. Electrogenic
bacteria hold great potential as new
biotherapeutics for treatments of free radical
associated human diseases.

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 2 FRIDAY OCTOBER 18TH 2024

PAUL CARLSON

OLIVER WORSLEY

Principal Investigator, CBER, FDA
Regulatory Considerations for
Microbiome Based Therapeutics• An overview of CMC requirementsfor Live Biotherapeutic Products• Discussion of assays for productcharacterization and release• Presentation of proof of principle study
assessing the use of MALDI-TOF for single
strain enumeration from multi-strain mixtures••

JESSICA O’CONNELL

Partner, Covington & Burling LLP
Skin Microbiome Case Study – IP
& regulations

ANGELA CHRISTIANO

50 MINUTE PANEL DISCUSSION

Food vs. pharma paths to market for probiotics
Deciding how to bring new innovative probiotics
to market is complicated. It involves analyzing
the many trade offs between being a food or adrug from each of several different angles. Thispanel will discuss the impacts of the following
considerations on creating a business plan:••••

Regulatory constraints
Supply chain set up
Path to ROIMarket/consumer demands

ZAC LEWIS (Chair)Principal, Lewpine Consulting

NOAH ZIMMERMAN

3:15-3:40

Associate Profesor, University ofCalgary
Proteolytic Activity of the VaginalMicrobiome: A Novel Therapeutic
Target?
In reproductive age women, a healthy vaginal
microbiome is dominated by Lactobacillus
species that protect the niche through the
production of lactic acid. However, 10–30% of
women exhibit anaerobic dysbiosis that cancause uncomfortable symptoms and resultin a clinical diagnosis of bacterial vaginosis(BV). Proteolytic activity is elevated during BV,
which in turn, is linked with poor outcomessuch as preterm birth and HIV acquisition.
Although this proteolytic activity has been
attributed to host proteases, we have shown
certain prevalent species of vaginal bacteria
secrete potent host-targeting proteases. Thesebacterial proteases mimic the activity of humanmatrix metalloproteases (MMPs) and degrade
cervical barrier proteins to promote bacterialtranslocation. Therapeutically targeting theseunique enzymes could help prevent BV andpromote sexual and reproductive health.

3:15-4:05

3:15-3:40

3:15-3:40•

LAURA SYCURO

Global Director, Clinical Innovation& Translation, IFF
Novel Akkermasia sp. formetabolic healthIn her presentation Dr. Maukonen will have a
deeper dive on a discovery program of a novel
Akkermansia sp. DSM33459 which showedsignificant differences in fatty acid profile andcarbon utilization as compared to the type strain.
It also showed agmatine production, suggesting
a potential novel mechanism for supporting
metabolic and cognitive health and was able todegrade extracellular ATP, suggesting a role inmodulating inflammation in the gut.
• An observational clinical study was performed
to collect fecal samples for microbiome andmetabolomic assessment. Strains of healthrelated bacterial species were isolated based on
the obtained data.
• Preclinical obesity model showed significant
improvement in body weight, total fat weight,
resistin, and insulin levels.
• Based on phenotypic features and phylogenetic
position, it is proposed that this isolate is apromising candidate for the management of
metabolic heath

2:50-3:15•

VP, Manufacturing, Rise
Therapeutics
Anaerobic development andmanufacturing: available tools forearly-stage companies, productdevelopment risks and mitigation
strategies
What are some of the key challenges
encountered in the development of anaerobiclines?
What are some key product development
risks that should be assessed, addressed anddeveloped early in the life cycle of the program
What strategies are available for early-stage
companies looking to embark on the
launch of a microbiome product that involves
an anaerobic organism

JOHANNA MAUKONEN

2:50-3:15

2:50-3:15

2:50-3:15

SATHYA JANARDHANAN

CEO & Co-Founder, Sequential
Leveraging Microbiome Samples
from US, UK and Singapore tocharacterise Female Health• Introduction to the vaginal microbiome andtechniques used to study it• 5,000 subject study on vaginal microbiome anddifferences between geographic regions, andethnicities, from US to Europe to Asia
• The development of Sequential Smart Probes toquantify the vaginal microbiome at strain levelto further characterise the diversity in healthand infection

Professor of Dermatology andGenetics & Development,
Columbia University
The Gut Microbiome-Hair Follicle
Connection in Alopecia Areata
The gut microbiome has emerged as an importantenvironmental contribution factor in many
autoimmune diseases. Our work in alopecia areata
points to the gut microbiome as a potential trigger
for the immune response against the hair follicle.
Recent evidence linking gut microbiome dysbiosis
to alopecia areata opens a new avenue ofinvestigation into restoration of the gut microbiome
to homeostasis as a potential therapeutic approachfor this and other autoimmune diseases.

Chief Technology Officer, Verb
Biotics

AMY SMITH

Director, Global Regulatory Strategy
Lead, IFF

DENISE KELLY

Investment Advisor, SeventurePartners

12TH MICROBIOME R&D & BUSINESS COLLABORATION / 9TH PROBIOTICS & PREBIOTICS / 6TH SKIN MICROBIOME & COSMECEUTICALS CONGRESS: USA 2024

CONGRESS SCHEDULE

DAY 2 FRIDAY OCTOBER 18TH 2024

RYAN GARRETT

Founder & CEO, FitBiomics

3:40-4:05

Conference Close

PING HU

JONATHAN SCHEIMAN

Co-Founder & CEO, Ancilia Biosciences
Deciphering and targeting the virome

3:15-4:05

4:05

ALEX SAKATOS

3:40-4:05

3:40-4:05

Head of Process Development,
Vedanta Biosciences
Critical Considerations of a
Successful Live Biotherapeutic
Product
Despite an abundance of academic researchdemonstrating the significance of the humanmicrobiome on health, well being, anddisease, converting this research into safe andefficacious FDA approved drugs has proved
challenging. Over the past ten years, Vedanta
has been a pioneer in applied science and CMC
aspects of LBPs with internal development
and manufacturing capabilities culminating in
32 strains produced for five clinical programs
including late phase clinical trials. This internal
development along with learnings from othercompanies in the field have revealed key
attributes of LBPs that are necessary to maximize
the chance of clinical success.

R&D Director, Principal Scientist,
Research & Development, Procter& Gamble
Exploring the Dynamics of the
Scalp and Skin Microbiomes and Applications
for Consumer Product Innovation
In recent years, the study of the humanmicrobiome has emerged as a fascinating
and promising field of research. The intricate
relationship between microorganisms andhuman health has opened new avenues fortherapeutic interventions and innovative
consumer product development. This
presentation will cover a few cases of how P&G
using multi-omics approach to examine scalp
and skin microbiomes under different conditions
to understand the mechanism of actions, selectbiomarkers and credential a technical story for
consumer product innovation.

CONGRESS SCHEDULE
2:55-3:45 ROUNDTABLE SESSION ONE
Roundtable 1:

JESSICA O’CONNELL

Partner, Covington & Burling LLP
Probiotics Claims and IP
Roundtable 2:

REN-HAU LAI

Director of Innovation and Product Development, Athletic Greens
The challenge of probiotic product development and the future
Roundtable 3:

STEPHANIE FRALEY

Associate Professor, Shu Chien-Gene Lay Dept of Bioengineering, UCSD
Antibiotics and Infant healthRoundtable 4:

CHERYL SEW HOY

CEO & Founder, Tiny Health
New discoveries leveraging at-home microbiome profiling and probiotic strain
tracking via shotgun metagenomics
Probiotic companies often have formulations that combine multiple strains and while some individualstrains are clinically backed, companies often have challenges generating robust clinical data at theformulation level to support product health claims. Shotgun sequencing presents a more accessible andreliable way for end consumers, nutrition companies and researchers to detect potential colonizationand functional effects from these probiotic supplements. These effects are much more pronounced in
the infant probiotic space where the infant gut is more uniquely adapted to colonize bifidobacterium
probiotics. We will discuss how these approaches can help the industry advance forward with better
observational and clinical evidence

DAY 2 FRIDAY OCTOBER 18TH 2024
12:10-1:00 ROUNDTABLE SESSION TWO
Roundtable 1:

TIINA ORASMÄE-MEDER

CEO and founder , Meder by Dr Tiina Meder
How to speak about a microbiome: educational challenge in skincare industry
The concept of the skin microbiome is relatively new, but the beauty industry has beenquick to develop products that interact with it. Communicating the benefits of these products to skinpractitioners and consumers, however, has been a challenge due to the complexity of the concept andvarying levels of scientific knowledge among target audiences. Brands need to tailor their messaging
to local culture, professional education levels, and press coverage. Providing clear explanations of
microbiome-friendly products and addressing frequently asked questions is crucial. Ongoing educationand training for skin therapists is essential to ensure they can confidently promote these innovative
skincare products.
Roundtable 2:

SATHYA JANARDHANAN

VP, Manufacturing, Rise Therapeutics
Specialty Probiotics and Live Biotherapeutic Products: gaps in the supply chain in thecurrent climate and strategies to secure clinical and commercial supply• In the current climate, where are some of the key gaps in LBP and Probiotic supply chains?
• What tools or resources are available to LBP/probiotic companies facing a supply cliff in the light of achanging production capacity landscape• Does the cost of goods in the LBP space match expectations for companies that are yet to scale?
What tools are available to navigate expensive development &amp; manufacturing leading up tocommercial viability?
Roundtable 3:

CRISTINA LLORENTE

Assistant Professor, Div. Gastroenterology, Dept. Medicine, UC San Diego
The Gut Microbiome's Impact on Liver Disease: Exploring Novel Therapies• The role of prebiotics and probiotics in modulating gut-liver axis interactions.
• Applications of fecal microbiome transplantation (FMT) in liver disease management.
• Novel preclinical studies utilizing bacteriophages as targeted therapies against microbial
dysbiosis in the context of liver health.
Roundtable 4:

AUBREY LEVITTCEO, Postbiotics Plus Research LLC
Bioactive compounds and the gut microbiome• The role postbiotics and bioactive compounds in gut health• How to measure efficacy• How to market and communicate the benefits of new product categories

POSTER PRESENTATIONSFREE POSTER PRESENTATIONS AND FLASH TALKS
Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an
excellent way to join the heart of this congress. In order to present a poster at the forum, you need to be registered as a delegate. Please note that there islimited space available and poster space is assigned on a first-come-first-served basis (subject to checks and successful registration).
Poster presentations are actively encouraged at this event and as such registered academic and industry delegates are invited to present
1 poster each for free.
• Posters are displayed for the full two days of the event.
• We have reserved two 50 minute sessions in track 1 for non-vendor authors to present a flash presentation of their poster in order to showcase theirwork.
• We also issue a poster eBook to all attendees containing your full abstract, and you can share your poster as a PDF after the meeting if you desire(optional).
MAKING A POSTER PRESENTATION
We will require the form Downloadable Here to be submitted by 27th September 2024.

SUSTAINABILITY GOALSSUSTAINABILITY
Venues with Sustainability Goals
We are committed to selecting venues with more sustainable practices. These will cover energy supply, food & waste, water use, recycling
and plastics. The Marriott La Jolla is Tripadvisor GreenLeaders Certified. The hotel website shows a carbon footprint of 11.6 kgs per roomnight. The hotel footprint calculator Greenview reveals that the US average is 17.6 kgs per night (higher for 4 & 5* hotels.)Catering
You will have some great food choices while you are with us. We have worked with the caterer to increase the proportion of plant-based
items. We have also built a plan with the venue to avoid waste through how they serve meals and how any leftovers are processed. Our aim
is that you have some great meals, whilst with us, but with less environmental impact by the time you leave.

TravelAn international meeting does involve travel but where it is practical, please consider more sustainable alternatives to flying. The app will
also have a discussion space to arrange ride shares.